Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Medchemcomm. 2013 May 2;4(6):1015–1017. doi: 10.1039/C3MD00082F

The use of 111Ag as a tool for studying biological distribution of silver-based antimicrobials

Tolulope A Aweda a, Oluwatayo Ikotun a, Tara Mastren a, Carolyn L Cannon b, Brian Wright c, Wiley J Youngs c, Cathy Cutler d, James Guthrie d, Suzanne E Lapi a,*
PMCID: PMC3733397  NIHMSID: NIHMS479057  PMID: 23930200

Abstract

Recently, there has been an emergence of significant interest in silver-based antimicrobials. Our goal was to develop a radioactive tracer for investigating the biological fate of such compounds. Purified 111Ag was incorporated into the methylated caffeine analogue, IC1 to yield the silver carbene complex designated as [111Ag]SCC1 and investigated in biodistribution studies.


Different antimicrobials have been developed over the years to treat bacterial lung infections. With increasing prevalence of pathogenic bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Acinetobacter baumannii (MRAB) and Psuedomonas aeruginosa gaining resistance to conventional antimicrobial agents such as penicillin, vancomycin, ampicillin, ceftazidime and kanamycin,1, 2 there is a challenge to continuously develop new effective antimicrobials. The use of silver as an antimicrobial agent can be dated as far back as the early 1800s until the birth of penicillin and other antibiotics.3 Due to the emergence of resistant microbial strains, an interest in the use of silver in the management of wound infection and as a topical antimicrobial has renewed recently.4, 5 Several studies have been published on the use of silver as an antimicrobial for in vivo therapy, of particular interest is the use of stable N-heterocyclic carbene metal complexes as silver delivery agents.69 Silver has long been used as a broad-spectrum anti-bacterial at very low concentrations,10 with very little evidence of bacterial resistance.11, 12 Although, the bactericidal mechanism of silver is not completely understood, it has been suggested that the interaction of Ag+ with thiol compounds or the DNA helical chains in bacteria cells could be the cause of the observed cell membrane damage or bacterial growth inhibition.13, 14 Since cationic silver shows very minimal toxicity and side effects (rare cosmetic side effect known as argyria),12, 15 new silver based compounds have been synthesized as potential antimicrobials for pulmonary infections related to cystic fibrosis.16, 17

Previously, silver was coupled to derivatives of caffeine-like xanthine compounds as shown in Scheme 1 to obtain silver N-heterocyclic carbene complexes (SCCs). These compounds have been shown to have a broad-spectrum antimicrobial activity, even against bacteria resistant to conventional antimicrobials.1820 The cytotoxicity, acute reaction and efficacy of the nebulized silver carbene complex designated as SCC1 has been investigated in mice models.18 In murine infection models, complete eradication of bacteria in the lungs was observed in more than 50% of the mice. These results demonstrate the potential of caffeine carbene derivatives as carriers of silver in lung infections therapies. Little, however, is known about the dose deposited in the lungs of these treated animals via the aerosol route. This information is important for the translation of these compounds to clinical studies and thus, prompted the following studies.

Scheme 1.

Scheme 1

Synthesis of SCC1 from caffeine

Our study investigates the dose delivered into the lungs via aerosol and the tissue distribution of a radiolabeled carbene complex in mice models. 111Ag was chosen as the radiotracer due to its favorable half-life, low beta and gamma energy and ease of production. 111Ag has a t½= 7.47 days, decays 92% by β emission (1.037 MeV) and has characteristic γ rays at energies of 245 keV (1.3%) and 342 keV (6.7%) useful for detection and monitoring by gamma spectroscopy.21 111Ag can be produced from neutron irradiation of Pd targets and subsequent β decay of 111Pd to 111Ag: (110Pd(n, γ) 111Pd (t½ = 23.4 m) → 111Ag) then purified using ion-exchange chromatography monitored via gamma spectroscopy. In the crude irradiated sample, the presence of Pd is followed using 109Pd (t½ = 13.7 h, γ = 88 keV, 100% β emission to excited energy levels or the ground state of 109Ag) which is co-produced during the irradiation of natural palladium (108Pd, 26.46% natural abundance). A representative gamma spectrum of the irradiated Pd target (109Pd, 88 keV) and purified 111Ag (97, 245, 342 keV) is shown in Figure S1. As shown in Table 1, a number of nuclear reactions are possible during the neutron bombardment of natural palladium. One of these reactions produce the metastable Ag isotope, 110mAg via neutron bombardment and subsequent β decay of 108Pd to 109Ag and thereafter 110mAg: (108Pd(n, γ) 109Pd (t½ = 13.7 h) → 109Ag; 109Ag(n, γ) 110mAg (657 keV, and 884 keV, t½ = 249.8 days)). 110mAg was observed along with 111Ag, thus can also be used to monitor the elution of silver from the ion-exchange resin.

Table 1.

Nuclear reactions and products produced during neutron bombardment of natural palladium

Reaction Target Percent Abundance Product (half-life) Subsequent decay product
102Pd(n, γ) 1.02 103Pd (16.99 d) 103Ag (1.1 h)
106Pd(n, γ) 27.33 107Pd (6.5 x 106 yr) 107Ag (stable)
107mPd (20.9 s) 107Pd
108Pd(n, γ) 26.46 109Pd (13.5 h) 109Ag (stable)
110Pd(n, γ) 11.72 111Pd (23.4 m) 111Ag (7.47 d)
109Ag(n, γ) [48.1]* 110mAg (249.8 d)
*

Stable isotope of Ag with natural abundance of 48.1%. Neutron capture leads to production of 110mAg, a long lived radiosilver contaminant.

Anion exchange chromatography (AG1-X8 resin) was used to separate the palladium ions from the silver ions using a reversed modified method described by Aardaneh et al.22 In nitric acid solutions (HNO3 ≥ 1M), Pd2+ forms anionic complexes such as [Pd(H2O)(NO3)3] and [Pd(NO3)4]2− which are retained strongly on the AG1-X8 resin,23 while Ag+ forms neutral AgNO3 species which adsorb weakly to the resin. Different acid concentrations and column lengths were investigated to determine the optimal elution conditions. Figure S2 shows a superior elution profile of 111Ag from AG1-X8 anion exchange resin packed in a long, thin column (0.7 x 20 cm) and eluted with 3M nitric acid as compared with 2M nitric acid or 3M nitric acid in a shorter column (1.0 x 10cm). The average recovery of pure 111Ag was calculated as (92.9 ± 23.7)% by comparing the activity measured before and after purification via gamma spectrometry. ICP-MS measurement of the eluted fractions demonstrated a final concentration of <25 ppb of Pd in all solutions used for subsequent radiolabeling which indicates that >99.9% of the palladium was removed by our purification process.

The isolated 111Ag recovered was used in in vivo studies either incorporated into a carbene or used as the nitrate or acetate salt. Synthesis of the carbene compound was accomplished as previously described by Kascatan-Nebioglu et al.16 111Ag was successfully incorporated into the xanthinium salt, IC1 with a radiochemical yield of (25.5 ± 2.5)%. The product was reconstituted in 0.24% acetic acid at a final pH of 7.0 for ex vivo biodistribution studies. The amount of radioactivity in each organ as a percent dose per gram administered per animal is shown below in Figure 1. Although, single and multiple aerosol dosing experiments were performed separately, no significant difference was observed in the biodistribution of the normal mice used. This observation could be attributed to the lack of entrapment of [111Ag]SCC1 in any organ except the lungs where it was continuously cleared and excreted daily with no cumulative dose observed after 3 days. Based on these findings, we concluded that one dose administration for 5 m was sufficient, resulting in a total dose received per mouse of (1.07 ± 0.12)% of the aerosolized dose. The average dose taken up in the lungs (% ID/g) of the mice was estimated to be (21.5 ± 1.2)% of the total dose received per mouse, thus (0.22 ± 0.01)% of the aerosolized dose. The presence of the radiotracer in the stomach and the intestine is indicative of activity that may have been coughed up from the airways and subsequently swallowed. Since, coughing is one of the natural ways in which the body gets rid of foreign particles dislodged in the respiratory airways,24, 25 it is reasonable to conclude that any activity in the stomach or intestine is associated with the coughing and swallowing process. Also, as shown in Figure S3, the multi-dosing animal chamber is airtight such that no activity reaches other body parts of the mice except the nose.

Fig. 1.

Fig. 1

Biodistribution of nebulized [111Ag]SCC1 in normal mice. Two dose delivery approaches; 1 aerosol dose for 5 m and 5 doses administered within 3 days were investigated. No significant difference was observed in the lungs or any organ due to the fast and continuous clearance of the radiotracer. Excretion data (urine and feces) is only given for the 1 dose cohort.

Conclusions

Silver-111 has been purified from neutron irradiated palladium targets as a carrier-free radioisotope and successfully incorporated into the methylated caffeine carrier, IC1 to yield [111Ag]SCC1. [111Ag]SCC1 was delivered into healthy mice via nebulization to determine the average deliverable dose. The 111Ag based compounds cleared mostly through feces with good accumulation in the lungs 24 h after nebulized dose delivery. Pre-clinical studies using 111Ag incorporated in SCC1 carbene as an antimicrobial compound show high drug dosing via nebulization and good lung retention. The average %ID/g in the lungs was observed to be 10–50 times greater than most of the other organs—liver, spleen, kidneys and bone. It is expected that the transportation of silver based therapeutics into and through the lungs of healthy animals would be different from that of infected mice with thick mucus and biofilm. Thus, it would be important to determine the biodistribution of the inhaled silver therapeutics in the lungs of infected mice or in polymeric artificial mucus. The results obtained indicate 111Ag is a useful radiotracer for investigating the biodistribution of silver therapeutics.

Supplementary Material

ESI

Acknowledgments

This work was supported by The National Institutes of Health under contract HHSN268201000046C.

Footnotes

Electronic Supplementary Information (ESI) available: Experimental details on the purification and separation of 111Ag from irradiated palladium wire, synthesis of 111Ag labeled carbenes, HPGe spectra and elution profiles. See DOI: 10.1039/b000000x/

Contributor Information

Tolulope A. Aweda, Email: awedat@mir.wustl.edu.

Oluwatayo Ikotun, Email: ikotuno@mir.wustl.edu.

Tara Mastren, Email: tmastren@wustl.edu.

Carolyn L. Cannon, Email: carolyn.cannon@utsouthwestern.edu.

Brian Wright, Email: bdw12@zips.uakron.edu.

Wiley J. Youngs, Email: youngs@uakron.edu.

Cathy Cutler, Email: CutlerC@missouri.edu.

James Guthrie, Email: GuthrieJM@missouri.edu.

Notes and references

  • 1.Boucher H, Miller LG, Razonable RR. Clin Infect Dis. 2010;51:S183–S197. doi: 10.1086/653519. [DOI] [PubMed] [Google Scholar]
  • 2.Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Antimicrob Agents Chemother. 2007;51:3471–3484. doi: 10.1128/AAC.01464-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Klasen HJ. Burns. 2000;26:117–130. doi: 10.1016/s0305-4179(99)00108-4. [DOI] [PubMed] [Google Scholar]
  • 4.Silver S, Phung L, Silver G. J Ind Microbiol Biotechnol. 2006;33:627–634. doi: 10.1007/s10295-006-0139-7. [DOI] [PubMed] [Google Scholar]
  • 5.Castellano JJ, Shafii SM, Ko F, Donate G, Wright TE, Mannari RJ, Payne WG, Smith DJ, Robson MC. Int Wound J. 2007;4:114–122. doi: 10.1111/j.1742-481X.2007.00316.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hindi KM, Panzner MJ, Tessier CA, Cannon CL, Youngs WJ. Chem Rev. 2009;109:3859–3884. doi: 10.1021/cr800500u. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Panzner MJ, Hindi KM, Wright BD, Taylor JB, Han DS, Youngs WJ, Cannon CL. Dalton Trans. 2009;0:7308–7313. doi: 10.1039/b907726j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Patil S, Deally A, Gleeson B, Muller-Bunz H, Paradisi F, Tacke M. Metallomics. 2011;3:74–88. doi: 10.1039/c0mt00034e. [DOI] [PubMed] [Google Scholar]
  • 9.Roymahapatra G, Mandal SM, Porto WF, Samanta T, Giri S, Dinda J, Franco OL, Chattaraj PK. Curr Med Chem. 2012;19:4184–4193. doi: 10.2174/092986712802430090. [DOI] [PubMed] [Google Scholar]
  • 10.Russell AD, Hugo WB. In: Prog Med Chem. Ellis GP, Luscombe DK, editors. Vol. 31. Elsevier; 1994. pp. 351–370. [DOI] [PubMed] [Google Scholar]
  • 11.Percival SL, Bowler PG, Russell D. J Hosp Infect. 2005;60:1–7. doi: 10.1016/j.jhin.2004.11.014. [DOI] [PubMed] [Google Scholar]
  • 12.Kascatan-Nebioglu A, Panzner MJ, Tessier CA, Cannon CL, Youngs WJ. Coord Chem Rev. 2007;251:884–895. [Google Scholar]
  • 13.Randall CP, Oyama LB, Bostock JM, Chopra I, O’Neill AJ. J Antimicrob Chemother. 2012 doi: 10.1093/jac/dks372. [DOI] [PubMed] [Google Scholar]
  • 14.Modak SM, Fox CL., Jr Biochem Pharmacol. 1973;22:2391–2404. doi: 10.1016/0006-2952(73)90341-9. [DOI] [PubMed] [Google Scholar]
  • 15.Hollinger MA. Crit Rev Toxicol. 1996;26:255–260. doi: 10.3109/10408449609012524. [DOI] [PubMed] [Google Scholar]
  • 16.Kascatan-Nebioglu A, Melaiye A, Hindi K, Durmus S, Panzner MJ, Hogue LA, Mallett RJ, Hovis CE, Coughenour M, Crosby SD, Milsted A, Ely DL, Tessier CA, Cannon CL, Youngs WJ. J Med Chem. 2006;49:6811–6818. doi: 10.1021/jm060711t. [DOI] [PubMed] [Google Scholar]
  • 17.Melaiye A, Simons RS, Milsted A, Pingitore F, Wesdemiotis C, Tessier CA, Youngs WJ. J Med Chem. 2004;47:973–977. doi: 10.1021/jm030262m. [DOI] [PubMed] [Google Scholar]
  • 18.Cannon CL, Hogue LA, Vajravelu RK, Capps GH, Ibricevic A, Hindi KM, Kascatan-Nebioglu A, Walter MJ, Brody SL, Youngs WJ. Antimicrob Agents Chemother. 2009;53:3285–3293. doi: 10.1128/AAC.00314-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Leid JG, Ditto AJ, Knapp A, Shah PN, Wright BD, Blust R, Christensen L, Clemons CB, Wilber JP, Young GW, Kang AG, Panzner MJ, Cannon CL, Yun YH, Youngs WJ, Seckinger NM, Cope EK. J Antimicrob Chemother. 2012;67:138–148. doi: 10.1093/jac/dkr408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Youngs WJ, Knapp AR, Wagers PO, Tessier CA. Dalton Trans. 2012;41:327–336. doi: 10.1039/c1dt11100k. [DOI] [PubMed] [Google Scholar]
  • 21.Chattopadhyay S, Vimalnath KV, Saha S, Korde A, Sarma HD, Pal S, Das MK. Appl Radiat and Isot. 2008;66:334–339. doi: 10.1016/j.apradiso.2007.09.003. [DOI] [PubMed] [Google Scholar]
  • 22.Aardaneh K, Raubenheimer H, van der Walt T, Vermeulen C, van der Meulen N. J Radioanal Nucl Chem. 2003;256:31–35. [Google Scholar]
  • 23.Kononova ON, Goryaeva NG, Dychko OV. Nat Sci. 2009;1:166–175. [Google Scholar]
  • 24.Geiser M, Kreyling WG. Part Fibre Toxicol. 2010;7:1743–8977. doi: 10.1186/1743-8977-7-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Nishino T, Isono S, Shinozuka N, Ishikawa T. The Journal of Physiology. 2008;586:649–658. doi: 10.1113/jphysiol.2007.145276. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ESI

RESOURCES